Fiche centre
Istituto Cardiocentro Ticino
Lugano — Switzerland
Essais liés4clinical trials
VilleLuganolocalisation
PaysSwitzerlandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02710435
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System | Maladie coronarienne | Non applicable | NCT06779630 | BIOFLOW-48 — Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions | RECRUITING |
| Maridebart cafraglutide | Insuffisance cardiaque | Phase 3 | NCT07037459 | MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING |
| Selatogrel | Maladie coronarienne | Phase 3 | NCT04957719 | SOS-AMI — Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | ENROLLING_BY_INVITATION |
| Reducer System | Maladie coronarienne | À vérifier | NCT02710435 | REDUCER-I: An Observational Study of the Neovasc Reducer™ System | ACTIVE_NOT_RECRUITING |